Cargando…
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors
BACKGROUND: Targeting the ubiquitin-proteasome pathway is a promising approach for anticancer strategies. Recently, we found Bik accumulation in cancer cell lines after they were treated with bortezomib. However, recent evidence indicates that proteasome inhibitors may also induce the accumulation o...
Autores principales: | Zhou, Wei, Hu, Jingzi, Tang, Haimei, Wang, Da, Huang, Xuefeng, He, Chao, Zhu, Hongbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226681/ https://www.ncbi.nlm.nih.gov/pubmed/22078414 http://dx.doi.org/10.1186/1471-2407-11-485 |
Ejemplares similares
-
Positioning of proteasome inhibitors in therapy of solid malignancies
por: Roeten, Margot S. F., et al.
Publicado: (2017) -
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages
por: Yuan, Bao-Zhu, et al.
Publicado: (2013) -
The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010) -
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation
por: Rapino, F, et al.
Publicado: (2013) -
Flavones induce neutrophil apoptosis by down-regulation of Mcl-1 via a proteasomal-dependent pathway
por: Lucas, Christopher D., et al.
Publicado: (2013)